Submitting annual reports on medicine development

This page provides information on the report that sponsors must submit to the European Medicines Agency (EMA) every year after their medicine receives an orphan designation, until they submit an application for marketing authorisation.

Sponsors need to use EMA's IRIS system to submit all post-designation activities, including annual reports. EMA will not be able to process any submissions outside of IRIS. For information and guidance on using IRIS, please see Applying for orphan designation.

Sponsors are no longer required to submit documents but need to complete the relevant fields in the IRIS system (there is an option to upload additional documents if appropriate).

These annual reports on development could provide information on the status of the development of the medicine, including:

  • a review of ongoing clinical studies;
  • a description of the investigation plan for the coming year;
  • any anticipated or current problems in the process, difficulties in testing and potential changes that may have an impact on the medicine's orphan designation.

If a sponsor withdraws a marketing authorisation application, or the application receives a negative opinion from the Committee for Medicinal Products for Human Use (CHMP), the sponsor needs to resume submitting annual reports on medicine development for the designated orphan medicine.

If the sponsor wishes to inform EMA about Changing the name or address of a sponsor or Transferring an orphan designation, this should not be done in the annual report. For this purpose it is necessary to undergo the procedure outlined in section G of the Guideline on the format and content of applications for designation as orphan medicinal products and on the transfer of designation form one sponsor to another(ENTR/6283/00).

How useful was this page?

Add your rating
Average
2 ratings
1 rating
25 ratings